Dementia and Alzheimer’s Disease Diagnosis, treatment and pharmaceutical care Flashcards

1
Q

What is dementia?

A
  • Dementia is a clinical syndrome that includes difficulties in memory, language, and behaviour which lead to a deterioration in the ability to perform activities of daily living

Whilst cognition may decline gradually as someone ages, dementia may be suspected when the speed and/or nature of this decline is distinct from the natural ageing process

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is cognition?

A
  • Memory
  • Language
  • Awareness and orientation
  • Learning and understanding
  • Attention/concentration
  • Reasoning
  • decision making/Problem solving
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Symptoms of dementia:

A

A spectrum of symptoms describe the dementias:

  • Loss of concentration/attention
  • Orientation problems
  • Memory problems (initially short term)
  • Mood and behaviour changes (and personality)
  • Impaired decision making and judgement
  • Later: Speech and swallowing difficulties
  • Later: Incontinence and mobility issues
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Three stages of dementia severity:

A

Mild: short term memory loss. Core activities of daily living (ADL) maintained but higher level functions impaired
Moderate: worsening cognition. Core ADL now affected. Challenging behaviours may become more prominent
Severe: apathy and dependency prominent. Long term memory loss. Many patients receiving 24 hour care

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is vascular dementia:

A

Decline can be gradual or sudden (stroke/TIA)
Memory may be better preserved
Physical symptoms include slurred speech, dizziness, inability to recognise objects, difficulty performing motor tasks
Emotional lability/depression common

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is Alzheimer’s disease:

A
Memory impairment most prominent feature early on
Difficulty finding words
Disorientation
Memory loss
Problems performing ADL
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is Dementia with Lewy Bodies (DLB):

A
  • Cognitive slowing important feature
  • Degeneration of motor function
  • Confusion, attention deficit, executive function and visuospatial ability problems common early in illness, not memory problems
    Three core features:
  • Fluctuating cognition, pronounced variation in attention/alertness
    Recurrent visual hallucinations
    Spontaneous Parkinsonianism
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Diagnosing dementia:

A
  • An accurate and comprehensive history is vital, including physical and mental state exam
  • Check routine haematology, biochemistry, thyroid, vitamin B12 and folate
  • Check mid-stream urine, X-Ray/ECG if required
  • Opportunistic screening – e.g. hospital admission, NHS Health Checks
  • CT and MRI scans can be used to exclude space occupying lesions such as tumours

According to ICD-10

  • Memory loss must be present
  • Plus decline in one other domain of cognition (e.g. judging, reasoning, planning) such as that it interferes with activities of daily living (ADLs)
  • Some change in social behaviour (e.g. irritable, apathy, lability)
  • Decline lasting at least 6 months

Need to inform DVLA on diagnosis

According to NICE, diagnosis should be supported by a referral to a specialist service such as a memory clinic, who perform a range of tests including those for cognition

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Diagnosis tests of cognition in dementia:

A

Mini mental state examination (MMSE)- ‘Listen carefully. I am going to say three words. You say them back after I stop. Ready? Here they are… apple [pause], penny [pause], table [pause]. Now repeat those words back to me.’
[Repeat up to 5 times, but score only the first trial.]

7 minute screen:
Benton Temporal Orientation Test: identify the correct day, month, year, date, time of day. Answers adjusted for how close they are to the correct answer.

6 item cognitive impairment test: Count backwards from 20-1
[Correct – 0 points] [one error – 2 points] [ >1 error – 4 points]

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Treating dementia – general principles:

A
  • Treatment is not curative
  • Multiple drug and non-drug treatments may be needed to control the illness

Treatment should be guided by a holistic view of the patient and their carer(s)

  • Identify and accommodate specific cultural, dietary, spiritual, age related and gender issues
  • Consider learning disability, communication difficulties, sensory impairment
  • Identify and address problems with nutrition and self-care
  • Ensure co-morbidities managed appropriately

Attempts should be made to facilitate community living wherever possible

Never stop trying to involve dementia patients in day to day decisions

Language very important part of providing services to those living with dementia

Speak to patients about Lasting Power of Attorney and Advance Decisions/Statements

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Pharmacological treatment for dementia:

A

Drug treatments are only licensed for AD so diagnosis is important

  • Acetlycholinesterase inhibitors (AChE-I) are the main drug treatment
  • -> Rivastigmine (also targets ButE), donepezil, galantamine. Drugs can prolong current level of functioning or improve symptoms
  • Memantine is a NMDA antagonist and is the only other drug licensed
  • No major differences in effectiveness between different AChE-I’s

Use AChE-I’s with caution in the following:

  • Sick sinus syndrome or cardiac conduction conditions (e.g. sinoatrial block)
  • Those at risk of ulcers
  • History of asthma/COPD
  • Renal/hepatic impairment, more specific advice for memantine

Adverse drug reactions (ADRs) of AChE inhibitors are often self limiting and include:

  • GI: N&V, anorexia, ulceration, upset
  • CNS: Alertness and agitation, hallucinations, dizziness, insomnia, seizures
  • GUS: Urinary incontinence
  • Cardiac: Bradycardia, sinoatrial/atrioventricular block

ADRs of memantine include: headache, dizziness, constipation, hypertension, somnolence

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Non-pharmacological treatment for dementia

A

Lifestyle factor modification is a significant part of dementia prevention/amelioration
- Stop smoking, tackle obesity, reduce alcohol, 5-a-day, proper exercise, sugar/salt/fat management

Familiarity and routine are important for maintaining independence and function

  • Keep a diary or use reminder charts
  • Remember rooms are designed to look like by-gone era’s

Enhancing visibility another avenue

  • Use colour and size to make things stand out, e.g. telephones, toilets and doorways
  • Orientation boards containing date, weather symbols and time

Consider holistic needs
- Cultural, religious, falls risk, SALT, dementia patients cannot change

  • Treat co-morbid depression/anxiety and sleep disorders
  • Cognitive stimulation therapy (CST)

Challenging behaviours
- Animal therapy, massage, music, multisensory stimulation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

NICE guidance

Treating Alzheimer’s Disease (AD):

A

AChE inhibitors rivastigmine, galantamine and donepezil recommended for mild-moderate AD
- Use drug with lowest acquisition cost, but can also consider ADR profile, adherence, interactions and co-morbidities

NMDA antagonist memantine recommended as monotherapy for:

  • Moderate AD, in those who cannot take a AChE (intolerance or contraindication)
  • Severe AD

Combination therapy with memantine should be:

  • Considered if moderate disease
  • Offered if severe disease

Only specialists in dementia should initiate treatment and carer’s views should be sought

Continue only if a worthwhile effect on cognitive, global, functional, behavioural symptoms
Review treatment regularly by specialist team

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

NICE guidance

Treating Vascular dementia (VD) and Dementia with Lewy Bodies (DLB)

A

DO NOT use AChE inhibitors or memantine for treatment of VD, except if co-morbid AD

Risk factor control continues to be central to VD treatment
Treating hypertension effective
However, not much conclusive evidence that treating hyperlipidaemia (with statins) or blood clotting abnormalities (with aspirin) have an effect on VD incidence or progression

Offer donepezil or rivastigmine to those with mild-moderate DLB, galantamine in reserve. Consider these in severe DLB. Offer memantine if AChE not tolerated/contraindicatred

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Pharmaceutical care of dementia:

A
  • All licensed treatments available as generics, but be wary of substitution

One third of AD patients may not respond to AChE-I at all

  • One third may show transient improvements before declining
  • One third may show steady state functioning before declining
  • In those who do not respond to AChE-I initially, switching useful for ~50%

Poor tolerability to one AChE-I does not mean poor tolerability to the others

When starting treatment, use low doses initially and increase after:
- 1/12 for galantamine and donepezil, 2/52 for rivastigmine, 1/52 for memantine

NICE: Do not stop AChE-I because of disease severity alone.
- Treatment interruptions result in rapid losses of effects, often not recoverable

Other hints and tips:

  • Change site of rivastigmine patch daily, avoiding previous sites for 14 days
  • Rivastigmine and galantamine should be ideally be given away from food

Need to consider swallowing ability for dementia patients

Covert administration of medicines

Remembering (and understanding need) to take tablets

Dementia drug formulations available:
Tablets – donepezil, rivastigmine, galantamine (also capsules), memantine
Soluble tablets – donepezil
Liquid – rivastigmine, galantamine, memantine
Patch – rivastigmine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Drugs to avoid in dementia where possible:

A
Anticholinergic (antimuscarinics)
Hyoscine hydrobromide (NOT butylbromide)
Procyclidine
Oxybutynin
Promethazine
Orphenadrine
Antidepressants 
Antipsychotics 
Alpha blockers
Prazosin
Tamsulosin
Opiates 
Benzodiazepines
Sedating antihistamines
Chlorphenamine, cyclizine, promethazine

Limited evidence for alternative remedies

See your directed reading – e.g. ACB scale

17
Q

BEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA (BPSD)

A

As well as cognitive decline, dementia patients may suffer with behavioural and psychological symptoms (BPSD)

These include agitation, wandering, aggression, abnormal vocalisations, mood changes, sleep disturbance and psychosis

Agitation may include
Verbal / physical 
Antisocial behaviours
Sexual arousal/aggression
Self harm
Apathy / withdrawal

First line treatment is non-drug measures and watchful waiting, with a central goal of preventing suffering and harm
Prevent self harm and harm to others

18
Q

Non-pharmacological management of BPSD:

A

Try to rule out other causes for BPSD
Use the acronym PAIN
- Physical problems – infection, pain, constipation, dehydration, malnourishment?
- Activity related – washing, dressing, bored?
- Iatrogenic – side effects of medication, inappropriate care?
- Noise and other environmental factors such as lighting

Non-drug treatments

  • Talking down and distraction, aromatherapy, music therapy
  • Snoezelen
  • Massage, reflexology
  • Psychoeducation for carers – understanding individual patients
  • Incontinence pads
  • Sleep – bright light therapy, routine
19
Q

Pharmacotherapy for BPSD?

A

Even without overt signs of pain, a trial of paracetamol might be worthwhile

Use pharmacotherapy only if severe distress or an immediate risk of harm to the person with dementia or others

Drug treatments include

  • Antipsychotics.
  • AChE inhibitors and memantine. Some evidence for AChE inhibitors of modest positive effects, NICE recommends use in DLB and in AD when other non-pharmacological treatments are not effective or inappropriate, and when antipsychotics are also inappropriate or ineffective. Less evidence for memantine
  • Antidepressants. Use SSRIs in some cases, evidence is weak

Risperidone is the only drug licensed for BPSD in the UK

Covert administration of medication may be required

20
Q

Antipsychotics and BPSD – avoid wherever possible

A

Older antipsychotics usually avoided
Parkinson’s symptoms, EPSE, falls and drowsiness, cognitive blunting

Lewy Body Dementia (DLB) and Parkinson’s dementia high risk groups

Increased risk of stroke and mortality with all antipsychotics now limit use
Possible mechanism due to orthostatic hypotension and tachycardia

Most evidence for risperidone/olanzapine in BPSD, but also greatest harm risk
Effect is modest at best

If used, must have clear target symptoms, use lowest effective dose, review after 1-2 weeks (NICE – 6 weeks)